aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923 candidate, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial for treating patients with interstitial lung diseases (ILDs), such as pulmonary sarcoidosis; and in Phase 1 clinical trial to treat chronic hypersensitivity pneumonitis and connective tissue disease ILD.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Phone858-731-8389
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees42
Next Earnings Date11/12/2019 (Estimated)
OptionableOptionable
aTyr Pharma (NASDAQ:LIFE) Frequently Asked Questions
What is aTyr Pharma's stock symbol?
aTyr Pharma trades on the NASDAQ under the ticker symbol "LIFE."
When did aTyr Pharma's stock split? How did aTyr Pharma's stock split work?
aTyr Pharma's stock reverse split on Monday, July 1st 2019. The 1-14 reverse split was announced on Friday, June 28th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 28th 2019. An investor that had 100 shares of aTyr Pharma stock prior to the reverse split would have 7 shares after the split.
How were aTyr Pharma's earnings last quarter?
aTyr Pharma Inc (NASDAQ:LIFE) posted its quarterly earnings results on Wednesday, August, 14th. The biotechnology company reported ($1.80) earnings per share for the quarter, beating the consensus estimate of ($2.74) by $0.94. The biotechnology company had revenue of $0.09 million for the quarter. View aTyr Pharma's Earnings History.
When is aTyr Pharma's next earnings date?
What price target have analysts set for LIFE?
2 brokerages have issued twelve-month price objectives for aTyr Pharma's stock. Their predictions range from $4.00 to $4.00. On average, they anticipate aTyr Pharma's share price to reach $4.00 in the next year. This suggests a possible upside of 5.5% from the stock's current price. View Analyst Price Targets for aTyr Pharma.
What is the consensus analysts' recommendation for aTyr Pharma?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for aTyr Pharma in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for aTyr Pharma.
Has aTyr Pharma been receiving favorable news coverage?
News headlines about LIFE stock have been trending somewhat positive recently, InfoTrie reports. InfoTrie rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. aTyr Pharma earned a news impact score of 1.8 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for aTyr Pharma.
Are investors shorting aTyr Pharma?
aTyr Pharma saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 121,000 shares, an increase of 7.3% from the August 30th total of 112,800 shares. Based on an average trading volume of 92,900 shares, the days-to-cover ratio is currently 1.3 days. Approximately 3.8% of the shares of the company are short sold. View aTyr Pharma's Current Options Chain.
Who are some of aTyr Pharma's key competitors?
Some companies that are related to aTyr Pharma include Applied Genetic Technologies (AGTC), Pluristem Therapeutics (PSTI), Neon Therapeutics (NTGN), Cidara Therapeutics (CDTX), Pharmacyte Biotech (PMCB), INmune Bio (INMB), Organovo (ONVO), Outlook Therapeutics (OTLK), BIONDVAX PHARMA/S (BVXV), Surface Oncology (SURF), BioCardia (BCDA), Entera Bio (ENTX), Microbot Medical (MBOT), Vical (VICL) and CytRx (CYTR).
What other stocks do shareholders of aTyr Pharma own?
Who are aTyr Pharma's key executives?
aTyr Pharma's management team includes the folowing people:
- Dr. Sanjay S. Shukla, Pres, CEO & Director (Age 47)
- Ms. Jill M. Broadfoot, CFO & Principal Accounting Officer (Age 57)
- Dr. John D. Mendlein, Strategic Advisor & Director (Age 59)
- Dr. David J. King, Scientific Consultant (Age 60)
- Xiang-Lei Yang Ph.D., Founder
When did aTyr Pharma IPO?
(LIFE) raised $76 million in an initial public offering on Thursday, May 7th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Citigroup acted as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers.
How do I buy shares of aTyr Pharma?
Shares of LIFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is aTyr Pharma's stock price today?
One share of LIFE stock can currently be purchased for approximately $3.79.
How big of a company is aTyr Pharma?
What is aTyr Pharma's official website?
How can I contact aTyr Pharma?
aTyr Pharma's mailing address is 3545 JOHN HOPKINS COURT SUITE 250, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-731-8389 or via email at [email protected]
MarketBeat Community Rating for aTyr Pharma (NASDAQ LIFE)
MarketBeat's community ratings are surveys of what our community members think about aTyr Pharma and other stocks. Vote "Outperform" if you believe LIFE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LIFE will underperform the S&P 500 over the long term. You may vote once every thirty days.
